Switch theme
Sign up to access all valuation multiples
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
2007
838
LTM Revenue $215M
LTM EBITDA -$368M
$277M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Iovance Biotherapeutics has a last 12-month revenue (LTM) of $215M and a last 12-month EBITDA of -$368M.
In the most recent fiscal year, Iovance Biotherapeutics achieved revenue of $164M and an EBITDA of -$352M.
Iovance Biotherapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Iovance Biotherapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $215M | XXX | $164M | XXX | XXX | XXX |
| Gross Profit | $61.7M | XXX | $40.1M | XXX | XXX | XXX |
| Gross Margin | 29% | XXX | 24% | XXX | XXX | XXX |
| EBITDA | -$368M | XXX | -$352M | XXX | XXX | XXX |
| EBITDA Margin | -171% | XXX | -214% | XXX | XXX | XXX |
| EBIT | -$392M | XXX | -$395M | XXX | XXX | XXX |
| EBIT Margin | -182% | XXX | -241% | XXX | XXX | XXX |
| Net Profit | -$369M | XXX | -$372M | XXX | XXX | XXX |
| Net Margin | -172% | XXX | -227% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Iovance Biotherapeutics's stock price is $2.
Iovance Biotherapeutics has current market cap of $583M, and EV of $277M.
See Iovance Biotherapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $277M | $583M | XXX | XXX | XXX | XXX | $-1.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Iovance Biotherapeutics has market cap of $583M and EV of $277M.
Iovance Biotherapeutics's trades at 1.7x EV/Revenue multiple, and -0.8x EV/EBITDA.
Equity research analysts estimate Iovance Biotherapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Iovance Biotherapeutics has a P/E ratio of -1.6x.
See valuation multiples for Iovance Biotherapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $583M | XXX | $583M | XXX | XXX | XXX |
| EV (current) | $277M | XXX | $277M | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | -0.8x | XXX | -0.8x | XXX | XXX | XXX |
| EV/EBIT | -0.7x | XXX | -0.7x | XXX | XXX | XXX |
| EV/Gross Profit | 4.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.6x | XXX | -1.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIovance Biotherapeutics's last 12 month revenue growth is 71%
Iovance Biotherapeutics's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.5M for the same period.
Iovance Biotherapeutics's rule of 40 is -35877% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Iovance Biotherapeutics's rule of X is 8% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Iovance Biotherapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 71% | XXX | 72% | XXX | XXX | XXX |
| EBITDA Margin | -171% | XXX | -214% | XXX | XXX | XXX |
| EBITDA Growth | -13% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -35877% | XXX | -143% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 8% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 172% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 265% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Iovance Biotherapeutics acquired XXX companies to date.
Last acquisition by Iovance Biotherapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Iovance Biotherapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Iovance Biotherapeutics founded? | Iovance Biotherapeutics was founded in 2007. |
| Where is Iovance Biotherapeutics headquartered? | Iovance Biotherapeutics is headquartered in United States of America. |
| How many employees does Iovance Biotherapeutics have? | As of today, Iovance Biotherapeutics has 838 employees. |
| Who is the CEO of Iovance Biotherapeutics? | Iovance Biotherapeutics's CEO is Dr. Frederick G. Vogt, J.D.. |
| Is Iovance Biotherapeutics publicy listed? | Yes, Iovance Biotherapeutics is a public company listed on NAS. |
| What is the stock symbol of Iovance Biotherapeutics? | Iovance Biotherapeutics trades under IOVA ticker. |
| When did Iovance Biotherapeutics go public? | Iovance Biotherapeutics went public in 2010. |
| Who are competitors of Iovance Biotherapeutics? | Similar companies to Iovance Biotherapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Iovance Biotherapeutics? | Iovance Biotherapeutics's current market cap is $583M |
| What is the current revenue of Iovance Biotherapeutics? | Iovance Biotherapeutics's last 12 months revenue is $215M. |
| What is the current revenue growth of Iovance Biotherapeutics? | Iovance Biotherapeutics revenue growth (NTM/LTM) is 71%. |
| What is the current EV/Revenue multiple of Iovance Biotherapeutics? | Current revenue multiple of Iovance Biotherapeutics is 1.3x. |
| Is Iovance Biotherapeutics profitable? | Yes, Iovance Biotherapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Iovance Biotherapeutics? | Iovance Biotherapeutics's last 12 months EBITDA is -$368M. |
| What is Iovance Biotherapeutics's EBITDA margin? | Iovance Biotherapeutics's last 12 months EBITDA margin is -171%. |
| What is the current EV/EBITDA multiple of Iovance Biotherapeutics? | Current EBITDA multiple of Iovance Biotherapeutics is -0.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
